Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹

此次收购为美敦力的疼痛治疗产品组合增添了定义品类的SPRINT® PNS技术，使其成为业界最广泛的产品组合。¹

GALWAY, Ireland

爱尔兰戈尔韦

,

，

July 16, 2026

2026年7月16日

/

/

PRNewswire

美通社

/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management.

/ -- 全球医疗技术领导者美敦力公司（纽约证券交易所代码：MDT）今日宣布，已完成对SPR Therapeutics, Inc.（SPR）的收购。SPR是一家私营医疗技术公司，也是短期经皮周围神经刺激（PNS）疗法领域的公认领导者，该疗法用于慢性及急性疼痛管理。

The acquisition is valued at $650 million, consisting of an upfront cash payment..

该收购交易估值为6.5亿美元，由一笔前期现金支付构成。

Chronic pain affects nearly 50 million U.S. adults

慢性疼痛影响着近5000万美国成年人

2

2

, and for some, it can significantly impact their mobility, sleep quality, work performance, and overall quality of life. PNS is a form of neuromodulation that delivers mild electrical stimulation near targeted peripheral nerves to help reduce pain. As a non-opioid and non-surgical therapy, PNS can expand pain management treatment options, support earlier intervention in the care continuum, and help create additional opportunities for individualized patient care..

对部分患者而言，这可能显著影响其行动能力、睡眠质量、工作表现以及整体生活质量。PNS（周围神经刺激）是一种神经调控疗法，通过在目标周围神经附近施加微弱的电刺激来帮助减轻疼痛。作为一种非阿片类药物且非手术的治疗方式，PNS能够拓展疼痛管理的治疗选择，支持在诊疗流程中更早进行干预，并为个体化患者护理创造更多机会。

SPR's FDA-cleared SPRINT® PNS System is a short-term therapy designed to provide pain relief using a 60-day, minimally invasive treatment approach that does not require a permanent implant. SPRINT® is supported by a growing body of clinical research, including multiple prospective clinical studies, case series, and multi-center randomized controlled trials.

SPR公司获得美国食品药品监督管理局（FDA）批准的SPRINT®外周神经刺激（PNS）系统是一种短期疗法，旨在通过为期60天的微创治疗方案提供疼痛缓解，且无需永久植入。SPRINT®得到了日益丰富的临床研究支持，包括多项前瞻性临床研究、病例系列研究以及多中心随机对照试验。

Pooled results from 13 studies show that 60% of patients achieved meaningful pain relief (≥50% reduction in pain intensity) at the end of the 60-day treatment completion, with responders experiencing an average 76% reduction in pain intensity. Across all patients, there was a 56% reduction in pain intensity..

汇总13项研究的结果显示，在60天治疗结束时，60%的患者获得了有临床意义的疼痛缓解（疼痛强度降低≥50%），其中有效应答者的疼痛强度平均降低了76%。在所有患者中，疼痛强度总体降低了56%。

3

3

'Medtronic is committed to expanding access to innovative therapies that can meaningfully improve patient lives,' said Domenico De Paolis, Interim President of the Neuromodulation Operating Unit, part of the Medtronic Neuroscience Portfolio. 'The addition of SPRINT® extends our ability to serve patients across the continuum of pain care and broadens patient access to a minimally invasive treatment option to address both chronic and acute pain.'.

“美敦力致力于扩大创新疗法的可及性，以切实改善患者生活，”美敦力神经科学产品组合下属神经调控业务部临时总裁多梅尼科·德保利斯表示。“SPRINT®的加入增强了我们在疼痛管理全程中服务患者的能力，并扩大了患者获得微创治疗选择的机会，以应对慢性疼痛和急性疼痛。”

'At SPR, our mission has always been to help people living with pain reclaim their lives,' said Maria Bennett, President, Founder, and Chief Executive Officer of SPR. 'We are proud of the impact our team has made in advancing innovative therapies that offer meaningful pain relief. Joining Medtronic enables us to build on that foundation, expand access to our technology, and serve more patients living with pain.'.

SPR 总裁、创始人兼首席执行官玛丽亚·贝内特表示：“在 SPR，我们的使命始终是帮助疼痛患者重获生活。我们自豪于团队在推进创新疗法方面所产生的影响，这些疗法为患者带来了切实的疼痛缓解。加入美敦利使我们能够在此基础上进一步发展，扩大我们技术的可及性，并为更多疼痛患者提供服务。”

This acquisition reflects Medtronic's continued focus on strategic deals that strengthen its leadership across core businesses. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and neutral to accretive thereafter. The company remains committed to pursuing high-growth opportunities that complement its portfolio and enhance therapy options for physicians and hospital partners..

此次收购反映了美敦力持续专注于通过战略性交易巩固其在核心业务领域的领导地位。预计该交易在2027财年对美敦力调整后每股收益的稀释影响微乎其微，此后将实现中性或增厚效应。公司仍致力于寻求高增长机会，以补充其产品组合，并为医生和医院合作伙伴提供更丰富的治疗选择。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考，更大胆行动。我们是美敦力。美敦力公司（Medtronic plc）总部位于爱尔兰戈尔韦，是全球领先的医疗科技公司，通过探索并找到解决方案，勇敢应对人类面临的最严峻健康挑战。我们的使命——减轻痛苦、恢复健康、延长寿命——将遍布150多个国家的95,000多名充满热情的员工凝聚成一个全球团队。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法涵盖70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监护系统等。凭借我们多元的知识储备、永不满足的好奇心以及帮助所有需要帮助之人的愿望，我们提供创新技术，每秒钟、每小时、每天都在改变着两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

随着我们推动以洞察为驱动的医疗护理、践行以人为本的体验，并为我们的世界带来更佳的成果，您将看到我们更多的作为。在我们所做的一切中，我们致力于缔造非凡。欲了解有关美敦力的更多信息，请访问。

medtronic.com

medtronic.com

and follow us on

并在关注我们

LinkedIn

领英

.

。

About SPR

关于SPR

SPR is a medical technology company focused on advancing minimally invasive therapies for the treatment of pain. Its SPRINT® PNS System is designed to deliver short-term peripheral nerve stimulation therapy for sustained pain relief of up to three months following treatment and is supported by a growing body of clinical evidence and expanding reimbursement coverage.

SPR 是一家医疗技术公司，专注于推进用于疼痛治疗的微创疗法。其 SPRINT® PNS 系统旨在提供短期周围神经刺激治疗，在治疗后可实现长达三个月的持续疼痛缓解，并得到日益丰富的临床证据和不断扩大的医保报销范围的支持。

For more information on SPR Therapeutics, visit .

如需了解更多关于SPR Therapeutics的信息，请访问。

sprpainrelief.com

sprpainrelief.com

and follow SPR on

并遵循 SPR 开启

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力在美国证券交易委员会存档的定期报告中所述的风险和不确定性。实际结果可能与预期结果存在重大差异。

Medtronic Contacts:

美敦力联系人：

Justin Paquette

贾斯汀·帕凯特

Ingrid Goldberg

英格丽德·戈德堡

Public Relations

公共关系

Investor Relations

投资者关系

+1-612-271-7935

+1-612-271-7935

investor.relations@medtronic.com

investor.relations@medtronic.com

References

参考文献

Medtronic SCS Value Summary FY25; Lo Bianco, G., et al. (2025). Barriers to neuromodulation. J Anesth Analg Crit Care, 5(1):3.

美敦科脊髓刺激器（SCS）2025财年价值总结；Lo Bianco, G. 等（2025）。神经调控的障碍。《麻醉、镇痛与重症监护杂志》，5(1):3。

Lucas JW, Sohi I. Chronic pain and high-impact chronic pain in U.S. adults, 2023. NCHS Data Brief, no 518. Hyattsville, MD: National Center for Health Statistics. 2024. DOI:

卢卡斯 JW，索希 I. 2023年美国成年人的慢性疼痛和高影响慢性疼痛。NCHS数据简报，第518号。马里兰州海厄茨维尔：国家健康统计中心。2024年。DOI:

https://dx.doi.org/10.15620/cdc/169630

https://dx.doi.org/10.15620/cdc/169630

.

。

SPR SPRINT® PNS System Indications for Use

SPR SPRINT® 周围神经刺激（PNS）系统适用范围

. SPR Pain Relief. Accessed July 2, 2026.

.SPR 止痛。访问于 2026 年 7 月 2 日。

https://www.sprpainrelief.com/indications

https://www.sprpainrelief.com/indications

SOURCE Medtronic plc

来源：美敦力公司